[Transplantation. Immunosuppression].
Increases in the volume of organ transplantation and in the supply of new organs have been accompanied by a dramatic surge of interest in chemical immunosuppression. In the 1950s, the selection of immunosuppressive drugs was limited to azathioprine and steroids, polyclonal antilymphocyte and anti-thymocyte globulins being added in the 1960s. The 1970s witnessed a real breakthrough with the introduction of the first second-generation selective immunosuppressant, cyclosporine. During the 1980s, the focus of interest shifted to biological agents, mainly monoclonal antibodies, though only one of these, anti-CD3 (OKT3), gained wide clinical use. Finally, in the early 1990s emerged a broad range of third-generation immunosuppressants, most of them with highly specific sites of action. At least half a dozen of these are currently undergoing clinical trials.
Häyry
P
P
Transplantationslaboratoriet, HUCS, Helsingfors.
Gannedahl
G
G
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016377:Organ Transplantation
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D016572:Cyclosporine
Tema transplantationer. Immunsuppression.